|
Delayed
Australian S.E.
21:27:59 2026-10-19 EDT
|
5-day change | 1st Jan Change | ||
| 0.3300 AUD | +13.79% |
|
+24.53% | -49.23% |
| 10-06 | Gavin William Brown Nominates Candidates to the Board of Recce Pharmaceuticals | CI |
| 10-06 | Recce Pharmaceuticals Solicits Proxies from Shareholders | CI |
Projected Income Statement: Recce Pharmaceuticals Ltd
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 4.311 | 5.236 | 7.705 | 9.939 | 12.5 | 54.3 |
| Change | - | - | 21.46% | 47.14% | 29% | 25.72% | 334.56% |
| EBITDA 1 | - | -12.8 | -16.49 | -19.81 | -13 | -21.96 | 36 |
| Change | - | - | -28.84% | -20.16% | 34.37% | -68.87% | 263.94% |
| EBIT 1 | - | -12.69 | -16.83 | -20.17 | -13.3 | -22.35 | 35.9 |
| Change | - | - | -32.67% | -19.8% | 34.04% | -67.98% | 260.66% |
| Interest Paid 1 | - | -0.1726 | -0.8066 | -1.15 | -1.493 | -0.3 | -2.6 |
| Earnings before Tax (EBT) 1 | - | -13.08 | -17.66 | -21.43 | -14.96 | -25.1 | 33.4 |
| Change | - | - | -35.06% | -21.33% | 30.18% | -67.75% | 233.08% |
| Net income 1 | -10.99 | -13.08 | -17.66 | -21.43 | -14.96 | -25.1 | 33.4 |
| Change | - | -19.03% | -35.06% | -21.33% | 30.18% | -67.75% | 233.08% |
| Announcement Date | 8/31/22 | 8/31/23 | 8/30/24 | 8/29/25 | 8/31/26 | - | - |
1AUD in Million
Estimates
Forecast Balance Sheet: Recce Pharmaceuticals Ltd
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1.56 | 4.42 | -10.4 | -2.69 | 25 | -48.1 |
| Change | - | - | 183.33% | -335.29% | 74.13% | 1,027.83% | -292.4% |
| Announcement Date | 8/31/22 | 8/31/23 | 8/30/24 | 8/29/25 | 8/31/26 | - | - |
1AUD in Million
Estimates
Cash Flow Forecast: Recce Pharmaceuticals Ltd
| Fiscal Period: June | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| CAPEX 1 | 0.0386 | 0.1419 | 0.0264 | 0.062 | 0.016 | - |
| Change | - | 267.33% | -81.43% | 135.18% | -74.18% | -100% |
| Free Cash Flow (FCF) 1 | -12.73 | -13.15 | -20.47 | -9.954 | -24.78 | 33.4 |
| Change | - | -3.34% | -55.65% | 51.37% | -148.94% | 234.79% |
| Announcement Date | 8/31/23 | 8/30/24 | 8/29/25 | 8/31/26 | - | - |
1AUD in Million
Estimates
Forecast Financial Ratios: Recce Pharmaceuticals Ltd
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | -296.84% | -314.88% | -257.14% | -130.83% | -175.74% | 66.3% |
| EBIT Margin (%) | - | - | -294.33% | -321.5% | -261.76% | -133.84% | -178.83% | 66.11% |
| EBT Margin (%) | - | - | -303.34% | -337.29% | -278.12% | -150.53% | -200.86% | 61.51% |
| Net margin (%) | - | - | -303.34% | -337.29% | -278.12% | -150.53% | -200.86% | 61.51% |
| FCF margin (%) | - | - | -295.18% | -251.14% | -265.66% | -100.15% | -198.3% | 61.51% |
| FCF / Net Income (%) | - | - | 97.31% | 74.46% | 95.52% | 66.53% | 98.73% | 100% |
Profitability | ||||||||
| ROA | -67.74% | -35.15% | -106.04% | -238.11% | -135.8% | -82.75% | - | - |
| ROE | -118.45% | -71.89% | -350.01% | 291.63% | 340.78% | 151.32% | - | - |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | -0.12x | -0.27x | - | - | -1.14x | - |
| Debt / Free cash flow | - | - | -0.12x | -0.34x | - | - | -1.01x | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | 0.9% | 2.71% | 0.34% | 0.62% | 0.13% | - |
| CAPEX / EBITDA (%) | - | - | -0.3% | -0.86% | -0.13% | -0.48% | -0.07% | - |
| CAPEX / FCF (%) | - | - | -0.3% | -1.08% | -0.13% | -0.62% | -0.06% | - |
Items per share | ||||||||
| Cash flow per share 1 | - | - | - | -0.0734 | -0.0863 | -0.0342 | -0.01 | 0.108 |
| Change | - | - | - | - | -17.49% | 60.37% | 70.76% | 1,180% |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| EPS 1 | - | -0.0631 | -0.0752 | -0.0997 | -0.0904 | -0.0517 | -0.085 | 0.111 |
| Change | - | - | -19.18% | -32.58% | 9.33% | 42.81% | -64.41% | 230.59% |
| Nbr of stocks (in thousands) | - | 177,647 | 178,254 | 203,987 | 288,372 | 289,183 | 305,770 | 305,770 |
| Announcement Date | - | 8/31/22 | 8/31/23 | 8/30/24 | 8/29/25 | 8/31/26 | - | - |
1AUD
Estimates
| 2027 * | 2028 * | |
|---|---|---|
| P/E | -3.41x | 2.61x |
| PBR | - | - |
| EV / Sales | 9.09x | 0.75x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
- Financials Recce Pharmaceuticals Ltd
Select your edition
All financial news and data tailored to specific country editions
